iCAD partners with Swedish team on AI for breast cancer
Computer-aided detection (CAD) developer iCAD will collaborate with researchers...Read more on AuntMinnie.comRelated Reading: iCAD to highlight AI for tomosynthesis at ECR iCAD touts clinical results with Xoft Axxent brachytherapy iCAD highlights study results of DBT software FDA OKs iCAD's breast density AI software iCAD touts study on radiation therapy savings
ConclusionPRT/PCRT is associated with low grades of fibrosis and a good to excellent long-term cosmetic outcome.
This report details our experience using accelerated partial breast irradiation (APBI) as a component of salvage breast conserving treatment.
Randomized trials in selected early stage breast cancer patients with up to 10 year follow-up have proven that Accelerated Partial Breast Irradiation (APBI) given via High Dose Rate (HDR) implant bid in 5 days is equivalent to whole breast External Radiation Therapy (XRT) given qd in 5-6 weeks in regard to breast tumor local recurrence (LR) [1-2]. However, complications with APBI implant in a Medicare database review have been significant, with 3.95% of women requiring Mastectomy, 16.2% developing infections, and another 16.3% experiencing non-infection complications including rib fractures, fat necrosis, and breast pain .
To compare radiation lung dose in patients with early-stage breast cancer treated with lumpectomy and intraoperative radiation therapy with CT-guided HDR brachytherapy (Precision Breast IORT; PB-IORT) and those treated with whole breast irradiation (WBI-DIBH) or partial breast irradiation (PB-DIBH) with deep inspiratory breath hold.
To evaluate the clinical outcome of early breast cancer (EBC) patients treated with high-dose-rate interstitial brachytherapy (HDR-IBT) based accelerated partial breast irradiation (APBI) or boost therapy plus whole breast radiation therapy (WBRT).
Diffusing alpha emitters Radiation Therapy (DaRT) is a unique brachytherapy treatment, in which highly-destructive short-lived alpha-emitting atoms are dispersed to a therapeutically-significant range inside the solid tumor. It was previously shown that in situ ablation by DaRT induces a systemic antitumor immune response, evidenced by prolonged survival and reduced rates of lung metastases and of primary- or challenged- tumor development. Here, we aimed to investigate strategies to boost the systemic antitumor immune response induced by DaRT.
To develop a simple and efficient prediction model for estimating the skin dose during intraoperative radiation therapy (IORT) for breast cancer that utilizes the ultrasound skin bridge readings obtained as part of the treatment preparation.
Conclusions: 3D-HDR-BT achieves favorable clinical outcomes with mild late toxicity in patients with locally rNPC. Introduction Nasopharyngeal carcinoma (NPC), a tumor of epithelial origin, is a malignant disease of the head and neck common in southern China, especially in Guangdong province (1). As a result of advances in modern imaging and irradiation techniques, the 5-year overall survival (OS) of patients with newly diagnosed NPC without metastasis has reached 75% after external beam radiotherapy (EBRT) in Asia (2, 3). However, local recurrence, which occurs in 18–40% of patients, remains a major reason for...
This report summarizes our program's experience developing and implementing PB-IORT.
ConclusionsBased on indirect comparisons, no differences in clinical outcomes were observed among diverse APBI techniques in published clinical trials that formally compared WBI to APBI. However wide confidence intervals and high risk of inconsistency precluded a sound conclusion. Further head-to-head clinical trials comparing different APBI techniques are required to confirm our findings. Studies comparing different techniques using individual participant data and/or real-life data from population-based studies/registries could also provide more robust results.